The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results

Biotech stocks saw a resurgence this week, as a post-earnings follow-up rally and company-specific news offered support. The iShares NASDAQ Biotechnology Index (ETF) IBB gained about 1.5 percent.

The following catalytic biotech events are set to occur this week:  

Conferences

  • 2018 European Society of Cardiology Congress: Aug. 25-29 in Munich, Germany
  • 13th European Congress on Epileptology: Aug. 26-30 in Vienna, Austria
  • International Conference on Molecular Biology and Medicine: Aug. 27-28 in Dubai, UAE
  • 8th Global Experts Meeting on Advances in Neurology and Neuropsychiatry: Aug. 27-28 in Tokyo, Japan
  • 5th International Conference on Glycobiology & Glycoproteomics: Aug. 27-28 in Toronto, Canada
  • 21st World Congress on Radiology & Cancer Research: Aug 27-28 in Toronto
  • 14th International Conference on Clinical Gastroenterology and Hepatology: Aug. 29-30 in Toronto
  • 5th International Conference on Neglected Tropical & Infectious Diseases: Aug. 29-30 in Boston
  • 5th Annual Congress on Rare Diseases and Orphan Drugs: Aug. 29-30 in Boston
  • 4th Annual Congress on Infectious Diseases: Aug. 29-30 in Boston
  • 4th World Congress on Parkinsons & Huntington Disease: Aug. 29-30 in Zurich, Switzerland
  • 4th International Conference on Epilepsy & Treatment: Aug. 29-30 in Zurich
  • 32nd Annual World Dentistry Summit: Aug. 31-Sept. 1 in Boston
  • 6th World Summit on Heart, Stroke & Neurological Disorders: Aug. 31-Sept. 1 in Boston
  • 14th World Summit on Alzheimer's Disease, Dementia Care Research and Awareness: Aug. 31-Sept. 1 in Boston

PDUFA Dates

Tuesday

Tetraphase Pharmaceuticals Inc TTPH awaits FDA decision on Eravacycline, a fully synthetic fluorocycline being developed for complicated intra-abdominal infections.

Thursday

The FDA is set to rule on Akcea Therapeutics Inc AKCA's NDA for Volanesorsen, a RNAi drug to treat patients with familial chylomicronemia syndrome. Akcea is a unit of Ionis Pharmaceuticals Inc IONS.

Clinical Trial Results

Pfizer Inc. PFE will present late-phase data for Tafamidis, a TTR amyloid cardiomyopathy medication, at the European Society of Cardiology Congress on Monday.

Esperion Therapeutics Inc ESPR is due to release Phase 3 data for bempedoic acid/ezetimibe, being evaluated for hypercholesterolemia.

Xenon Pharmaceuticals Inc XENE is due to present Phase 1 data for its epilepsy treatment candidate XEN101 at the European Congress on Epileptology.

TG Therapeutics Inc common stock TGTX has scheduled the release of Phase 3 UNITY-CLL study's top-line data for its TG-1101 and TGR-1202 combo to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma for the end of summer 2018.

Related Links:

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPreviewsFDATop StoriesTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...